UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 28, 2005
PRO-PHARMACEUTICALS, INC.
- -------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
Nevada 000-32877 04-3562325
- -------------------------------------------------------------------------------
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
189 Wells Avenue, Newton, Massachusetts 02459
- ----------------------------------------- ----------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (617) 559-0033
---------------
Not Applicable
- --------------------------------------------------------------------------------
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
[_] Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
[_] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[_] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[_] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events.
On July 28, 2005, Pro-Pharmaceuticals, Inc. issued a news release announcing the
termination of SEC investigation. A copy of Pro-Pharmaceuticals' news release is
attached as Exhibit 99.1 hereto and incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits.
(c) Exhibits
99.1 News release of Pro-Pharmaceuticals, Inc. dated July 28, 2005.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
PRO-PHARMACEUTICALS, INC.
By: /s/ David Platt
---------------------------------
David Platt
President and
Chief Executive Officer
Date: July 28, 2005
Exhibit 99.1
Pro-Pharmaceuticals Announces Termination of SEC Investigation
NEWTON, Mass.--(BUSINESS WIRE)--July 28, 2005--Pro-Pharmaceuticals, Inc.
(Amex: PRW), a developer of novel cancer therapeutics to target cancer
cells through carbohydrate chemistry, today received written notification
from the Securities and Exchange Commission that the SEC has terminated
its investigation of the Company, begun in October 2003, without
recommendation of any enforcement action.
Pro-Pharmaceuticals, Inc. - Advancing Drugs Through
Glycoscience(R)
Pro-Pharmaceuticals is a drug development company commercializing
a new generation of anti-cancer treatments using carbohydrate
compounds to Glyco-Upgrade(TM) the safety and efficacy of FDA-approved
chemotherapy drugs. The Company has been conducting pre-clinical
studies for irinotecan, doxorubicin, oxaliplatin, paclitaxel,
cisplatin, and most recently with bevacizumab both in combination with
DAVANAT(R) and other polysaccharide compounds. Human colon and breast
xenography are being used to optimize formulations and results show
that DAVANAT(R) exhibits a broad spectrum of activity with tested
drugs. Additional information is available at
www.pro-pharmaceuticals.com.
FORWARD LOOKING STATEMENTS: Any statements in this news release
about future expectations, plans and prospects for the Company,
including without limitation statements containing the words
"believes," "anticipates," "plans," "expects," and similar
expressions, constitute forward-looking statements as defined in the
"safe harbor" provisions of the Private Securities Litigation Reform
Act of 1995. Because of uncertainties and risks facing the Company,
many of which are outside of the Company's control, future events
could cause actual results to differ materially from those indicated
by such statements. More information about those risks and
uncertainties is contained and discussed in the "Management Discussion
and Analysis of Financial Condition and Results of Operations" and
"Risk Factors" sections of the Company's most recent quarterly or
annual report and in the Company's other reports filed with the
Securities and Exchange Commission. The forward-looking statements
herein represent the Company's views as of the date of this press
release and should not be relied upon to represent the Company's views
as of a subsequent date. While the Company anticipates that subsequent
events may cause the Company's views to change, the Company disclaims
any obligation to update such forward-looking statements.
DAVANAT and Advancing Drugs Through Glycoscience are registered
trademarks of Pro-Pharmaceuticals. Glyco-Upgrade, CARBOSOME and
UNIVERSAL CARBOHYDRATE LINKER TECHNOLOGY are trademarks of
Pro-Pharmaceuticals.
CONTACT: Pro-Pharmaceuticals, Inc.
Anthony D. Squeglia, 617-559-0033
squeglia@pro-pharmaceuticals.com.